HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Verona Pharma (NASDAQ:VRNA) and maintained a price target of $32.
August 04, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verona Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $32.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $32 indicates the firm's continued confidence in the stock's potential, which could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100